Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Shan Zhou, Fang-Ling Zhao, Shuang-Hu Wang, Yi-Ran Wang, Yun Hong, Quan Zhou, Pei-Wu Geng, Qing-Feng Luo, Jian-Ping Cai & Da-Peng Dai. (2023) Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo. Pharmaceutical Biology 61:1, pages 356-361.
Read now
Read now
Yun Hong, Da-Peng Dai, Jian-Ping Cai, Shuang-Hu Wang, Yi-Ran Wang, Fang-Ling Zhao, Shan Zhou, Quan Zhou, Pei-Wu Geng, Yun-Fang Zhou, Xue Xu, Ji-Hua Shi & Qing-Feng Luo. (2022) Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo. Drug Design, Development and Therapy 16, pages 1779-1789.
Read now
Read now
Jianwei Yun, Zhiping Wu, Guoqing Qi, Tiyun Han & Dekui Zhang. (2021) The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Review of Gastroenterology & Hepatology 15:2, pages 149-157.
Read now
Read now
Jiquan Shen, Bo Wang, Shuanghu Wang, Feifei Chen, Deru Meng, Hui Jiang, Yunfang Zhou, Peiwu Geng, Quan Zhou & Bin Liu. (2020) Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats. Drug Design, Development and Therapy 14, pages 2199-2206.
Read now
Read now
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli & Edoardo Savarino. (2017) Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy 18:11, pages 1145-1152.
Read now
Read now
Articles from other publishers (38)
Matt Shirley. (2024) Vonoprazan: A Review in Helicobacter pylori Infection. Drugs 84:3, pages 319-327.
Crossref
Crossref
Kunfeng Yan, Xiaorong Dai, Zhenxing Li, Weiwei Rong, Lei Chen & Xinxin Diao. (2024)
Clinical Study on the Eradication of
Helicobacter pylori
by Vonoprazan Combined with Amoxicillin for 10‐Day Dual Therapy
. Clinical Pharmacology in Drug Development 13:3, pages 240-247.
Crossref
Crossref
Kenjiro Okubo, Toshiyuki Kudo, Sae Yoshihara, Yu Nakabayashi, Kana Nakauchi, Akimi Tanaka, Moe Saito, Ayumi Tsujisawa, Hitomi Goda, Yoshiaki Yamagishi, Chinatsu Otake, Kosho Makino, Hideyo Takahashi & Kiyomi Ito. (2024) Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil. Drug Metabolism and Pharmacokinetics 54, pages 100537.
Crossref
Crossref
Sarita Ratana‐Amornpin, Likasith Sanglutong, Thanee Eiamsitrakoon, Sith Siramolpiwat, David Y. Graham & Varocha Mahachai. (2023)
Pilot studies of vonoprazan‐containing
Helicobacter pylori
eradication therapy suggest Thailand may be more similar to the
US
than Japan
. Helicobacter 28:6.
Crossref
Crossref
Na‐Yun Su, Qing Shi, Hao Mei, Jie Hu, Yu‐Xiang Liu, Han‐Ning Liu, Heng‐Qi Liu, Yan Guo, Xing‐wei Wang & Chun‐Hui Lan. (2023)
Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary
Helicobacter pylori
infection: A propensity score matching analysis
. Helicobacter 28:5.
Crossref
Crossref
K Manimekalai, R Sudar Codi, Navinraja Komal Veererathinakumar & Vimala Ananthy. (2023) Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder. SBV Journal of Basic, Clinical and Applied Health Science 6:2, pages 33-38.
Crossref
Crossref
Darcy J. Mulford, Diane Ramsden, Liming Zhang, Ingrid Michon, Eckhard Leifke, Neila Smith, Hannah M. Jones & Carmelo Scarpignato. (2023)
Tiered approach to evaluate the
CYP3A
victim and perpetrator drug–drug interaction potential for vonoprazan using
PBPK
modeling and clinical data to inform labeling
. CPT: Pharmacometrics & Systems Pharmacology 12:4, pages 532-544.
Crossref
Crossref
Soichiro Sue, Masaaki Kondo, Takeshi Sato, Hiroyuki Oka, Katsuyuki Sanga, Tsuyoshi Ogashiwa, Mao Matsubayashi, Hiroaki Kaneko, Kuniyasu Irie & Shin Maeda. (2022)
Vonoprazan and high‐dose amoxicillin dual therapy for
Helicobacter pylori
first‐line eradication: A single‐arm, interventional study
. JGH Open 7:1, pages 55-60.
Crossref
Crossref
William D. Chey, Francis Mégraud, Loren Laine, Luis J. López, Barbara J. Hunt & Colin W. Howden. (2022) Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 163:3, pages 608-619.
Crossref
Crossref
Kazumi Inokuchi, Hideki Mori, Juntaro Matsuzaki, Kenro Hirata, Yosuke Harada, Yoshimasa Saito, Hidekazu Suzuki, Takanori Kanai & Tatsuhiro Masaoka. (2022)
Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line
Helicobacter pylori
eradication regimen
. Helicobacter 27:4.
Crossref
Crossref
Carmelo Scarpignato, Eckhard Leifke, Neila Smith, Darcy J. Mulford, Gezim Lahu, Axel Facius & Colin W. Howden. (2022) A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. The Journal of Clinical Pharmacology 62:6, pages 801-811.
Crossref
Crossref
Biyue Lin, Jingping Kou, Qingbo Xiao, Shuming Wu, Ji'an Hu, Jianbing Li, Zhu Zhu, Xinglin Zhou, Libo Xin, Yanhua Li & Zhongqing Wang. (2022) Identification, characterization, synthesis of major metabolites biotransformed from vonoprazan fumarate. Tetrahedron 108, pages 132669.
Crossref
Crossref
Darcy J. Mulford, Eckhard Leifke, Mark Hibberd & Colin W. Howden. (2021) The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan. Clinical Pharmacology in Drug Development 11:2, pages 278-284.
Crossref
Crossref
Ming-Shu Wang, Yi Gong, Lin-Sheng Zhuo, Xing-Xing Shi, Yan-Guang Tian, Chang-Kang Huang, Wei Huang & Guang-Fu Yang. (2022) Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept. Research 2022.
Crossref
Crossref
Soichiro Sue & Shin Maeda. (2021)
Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Helicobacter pylori
Eradication?
. Gut and Liver 15:6, pages 799-810.
Crossref
Crossref
Qiuyue Huang, Zongming Shi, Hong Cheng, Hui Ye & Xuezhi Zhang. (2021) Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology 55:10, pages 856-864.
Crossref
Crossref
Yoshiharu Suzuki, Takuya Yoshihashi, Kazuhiro Takahashi, Kinji Furuya, Nobuhiro Ohkohchi, Tatsuya Oda & Masato Homma. (2021) Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients. Journal of Clinical Medicine 10:17, pages 3964.
Crossref
Crossref
Shu Kiyotoki, Jun Nishikawa, Jutaro Miyamoto, Koji Tanigawa, Seiji Tsuchida, Ryo Kawasato, Takao Nakashima, Takakazu Furutani, Hirokazu Ozawa, Mitsuru Yasunaga & Isao Sakaida. (2021) Delay of endoscopic submucosal dissection-induced gastric ulcer healing by methotrexate. Clinical Journal of Gastroenterology 14:3, pages 754-758.
Crossref
Crossref
Shogo Watari, Motoo Araki, Jun Matsumoto, Kasumi Yoshinaga, Takanori Sekito, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Noritaka Ariyoshi, Jun Wada, Masami Watanabe, Toyohiko Watanabe & Yasutomo Nasu. (2021) Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: correlation with cytochrome P450 gene polymorphisms. Drug Metabolism and Pharmacokinetics, pages 100407.
Crossref
Crossref
Yousef Abdel‐Aziz, David C. Metz & Colin W. Howden. (2021) Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders. Alimentary Pharmacology & Therapeutics 53:7, pages 794-809.
Crossref
Crossref
Seiji Koga, Satoshi Ikeda, Ryohei Akashi, Tsuyoshi Yonekura, Hiroaki Kawano & Koji Maemura. (2021) Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y<sub>12</sub> Assay in Patients With Coronary Artery Disease. Circulation Reports 3:1, pages 26-33.
Crossref
Crossref
Takanori Mei, Hiroshi Noguchi, Kimitaka Suetsugu, Yu Hisadome, Keizo Kaku, Yasuhiro Okabe, Satohiro Masuda & Masafumi Nakamura. (2020) Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients. Biological and Pharmaceutical Bulletin 43:10, pages 1600-1603.
Crossref
Crossref
Mitsushige Sugimoto, Daiki Hira, Masaki Murata, Takashi Kawai & Tomohiro Terada. (2020) Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy. Antibiotics 9:10, pages 645.
Crossref
Crossref
Wei-min Kong, Bin-bin Sun, Zhong-jian Wang, Xiao-ke Zheng, Kai-jing Zhao, Yang Chen, Jia-xin Zhang, Pei-hua Liu, Liang Zhu, Ru-jun Xu, Ping Li, Li Liu & Xiao-dong Liu. (2020) Physiologically based pharmacokinetic–pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacologica Sinica 41:6, pages 852-865.
Crossref
Crossref
Yiran Wang, Changxiong Wang, Shuanghu Wang, Quan Zhou, Dapeng Dai, Jihua Shi, Xue Xu & Qingfeng Luo. (2020) Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. Frontiers in Pharmacology 11.
Crossref
Crossref
Shu Kiyotoki, Jun Nishikawa & Isao Sakaida. (2020) Efficacy of Vonoprazan for <i>Helicobacter pylori</i> Eradication. Internal Medicine 59:2, pages 153-161.
Crossref
Crossref
Mariko Hojo, Daisuke Asaoka, Tsutomu Takeda, Yuji Shimada, Kenshi Matsumoto, Kohei Matsumoto, Noboru Yatagai, Yoichi Akazawa, Kumiko Ueda, Hiroya Ueyama & Akihito Nagahara. (2020)
Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of
Helicobacter pylori
infection
. Therapeutic Advances in Gastroenterology 13, pages 175628482096624.
Crossref
Crossref
Ryohkan Funakoshi, Yukana Tomoda, Toshiyuki Kudo, Kenichi Furihata, Hiroyuki Kusuhara & Kiyomi Ito. (2019) Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. British Journal of Clinical Pharmacology 85:7, pages 1454-1463.
Crossref
Crossref
Mitsuhiro Nishihara, Hitomi Yamasaki, Richard Czerniak & Helen Jenkins. (2018) In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel. European Journal of Drug Metabolism and Pharmacokinetics 44:2, pages 217-227.
Crossref
Crossref
Mitsushige Sugimoto & Yoshio Yamaoka. (2019) Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Frontiers in Pharmacology 9.
Crossref
Crossref
Shuichi Miyamoto, Momoko Tsuda, Mototsugu Kato, Katsuhiro Mabe, Shuichi Muto, Shoko Ono, Yuichi Shimizu & Naoya Sakamoto. (2019) Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. Journal of Clinical Biochemistry and Nutrition 64:2, pages 174-179.
Crossref
Crossref
Xiangge Tian, Chao Wang, Peipei Dong, Yue An, Xinyu Zhao, Weiru Jiang, Gang Wang, Jie Hou, Lei Feng, Yan Wang, Guangbo Ge, Xiaokui Huo, Jing Ning & Xiaochi Ma. (2018) Arenobufagin is a novel isoform-specific probe for sensing human sulfotransferase 2A1. Acta Pharmaceutica Sinica B 8:5, pages 784-794.
Crossref
Crossref
Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga & Kazuhide Higuchi. (2018) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 97:3, pages 212-218.
Crossref
Crossref
Yasuaki Ishii, Hiroaki Yamada, Takeshi Sato, Soichiro Sue, Hiroaki Kaneko, Kuniyasu Irie, Tomohiko Sasaki, Toshihide Tamura, Ryosuke Ikeda, Takehide Fukuchi, Ryosuke Kobayashi, Makomo Makazu, Chiko Sato, Kingo Hirasawa, Masaaki Kondo, Wataru Shibata & Shin Maeda. (2018) Effects of Vonoprazan Compared with Esomeprazole on the Healing of Artificial Postendoscopic Submucosal Dissection Ulcers: A Prospective, Multicenter, Two-Arm, Randomized Controlled Trial. Gastroenterology Research and Practice 2018, pages 1-6.
Crossref
Crossref
Hideki Mizuno, Kazutoshi Yamada, Keiji Minouchi, Shinji Kamiyamamoto & Yoshinobu Hinoue. (2017) Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Biomedical Reports.
Crossref
Crossref
Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu & Qingwei Wang. (2017) Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 1059, pages 56-65.
Crossref
Crossref
Shintaro Hoshino, Noriyuki Kawami, Nana Takenouchi, Mariko Umezawa, Yuriko Hanada, Yoshimasa Hoshikawa, Tetsuro Kawagoe, Hirohito Sano, Yoshio Hoshihara, Tsutomu Nomura & Katsuhiko Iwakiri. (2017) Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion 95:2, pages 156-161.
Crossref
Crossref
Yuuichi Sakurai, Madoka Shiino, Sayako Horii, Hiroyuki Okamoto, Koki Nakamura, Akira Nishimura & Yukikuni Sakata. (2016) Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men. Clinical Drug Investigation 37:1, pages 39-49.
Crossref
Crossref